Please login to the form below

Not currently logged in
Email:
Password:

CSU

This page shows the latest CSU news and features for those working in and with pharma, biotech and healthcare.

90TEN and ICG win market research award at Communiqué 2015

90TEN and ICG win market research award at Communiqué 2015

Their'Wheals of Despair'campaign, created for Novartis UK, focused on chronic spontaneous urticaria (CSU) - a condition that was until recently a mystery to many doctors and almost completely unknown to ... Characterised by excruciating wheals, swelling

Latest news

  • NICE set to back Novartis' Xolair for skin condition CSU NICE set to back Novartis' Xolair for skin condition CSU

    NICE set to back Novartis' Xolair for skin condition CSU. Issues final draft guidance on the treatment's use as an add-on for chronic spontaneous urticaria. ... CSU is often characterised by itching and hives, or wheals, that recurs on a daily basis, or

  • Novartis' dermatology plans advance with Xolair approval Novartis' dermatology plans advance with Xolair approval

    Xolair for CSU is one of two drugs nearing the market in the dermatology category that Novartis has high hopes for. ... having the CSU market to itself for up to 10 years, as there are no competitors on the horizon at the moment.

  • CHMP backs Xolair for severe hives CHMP backs Xolair for severe hives

    Around half of all CSU patients do not respond even to high-dose antihistamine therapy. ... CSU leaves patients in constant fear of when the next attack is going to occur,” he added.

  • Novartis' omalizumab effective in chronic skin disease Novartis' omalizumab effective in chronic skin disease

    The active ingredient in Xolair (omalizumab) has been found to be effective as a treatment for a chronic and debilitating form of hives known as chronic spontaneous urticaria (CSU) in the ... Novartis filed for approval of omalizumab a few weeks ago as a

  • Novartis' omalizumab on track for filing in serious skin disease Novartis' omalizumab on track for filing in serious skin disease

    CSU occurs in around 0.5 to 1 per cent of the world's population. ... Novartis has been rolling out a new pre-filled syringe formulation of Xolair to try to drive sales, and approval in CSU could add another string to Xolair's bow.

More from news
Approximately 1 fully matching, plus 5 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Double Communiqué award win for 90TEN

    Despite affecting up to 500, 000 Britons and having a major impact on quality of life, chronic spon taneous urticaria (CSU) – a type of severe hives – was, until recently, a mystery ... compelling patient resource and a hard-hitting campaign full of

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics